Investing in weight-loss drugs, and why everyone’s talking about student loans

On this episode of the AJ Bell Money & Markets podcast, how financial markets reacted to speculation around the future of Keir Starmer as UK prime minister. [02:00] 

Dan Coatsworth and Tom Sieber unpack the latest results from Shell, BP and Barclays. [05:05] 

AI has haunted parts of the stock market once again, with financial comparison websites and insurance brokers the latest victims as investors fear major disruption to their business. [11:12] 

There was some remarkable news in the pharmaceutical space as Novo Nordisk battled Him & Her’s amid controversy around the launch of copycat weight-loss drugs. The pod team explore the weight loss drug space in more detail and explain why one analyst thinks Greggs is a major loser as people slim down. [15:05] 

Dan talks to Trevor Polishchuk from Worldwide Healthcare about how Eli Lilly has scored the top slot in the weight-loss drug market [24:13]. Martin Gamble chats to Oliver Kenyon from RTW Investment about other names to watch in this space. [30:13] 

Charlene Young is on the show to explain why everyone’s talking about student loans. [33:00] 

Finally, Danni Hewson talks to Pathos Communications about its experiences of listing on the UK stock market and the use of AI in the public relations industry. [45:32]